The tariff classification of BHV-1600 from China
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- The applicable subheading for the subject merchandise will be 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” The rate of duty will be free.
Ruling text
In your letter dated October 24, 2025, you requested a tariff classification ruling on BHV-1600. This ruling request was submitted by Kirti Jadeja, Global Trade Advisory, Deloitte Tax LLP. BHV-1600 is a novel bifunctional extracellular protein degrader designed to selectively bind circulating anti-1AR autoantibodies, redirecting them to the liver for ASGPR-mediated endolysosomal degradation. BHV1600 is being developed for the treatment of Dilated Cardiomyopathy (DCMs) caused by humoral autoimmune response to 1AR.
In your letter, you indicated the BHV-1600 will be imported for investigational research and drug development purposes to conduct Phase 1 through Phase 3 clinical trials. The BHV-1600 will be imported as the BHV-1600 drug product and BHV-1600 Active Pharmaceutical Ingredient (API). Biohaven Pharmaceuticals, Inc. (“Biohaven”) has an approved IND from the FDA for BHV-1600 to support testing and clinical trials for drug development.
The BHV-1600 drug product will be used in Phase 1 clinical trial through Phase 3 clinical trial studies to test for efficacy in treating Dilated cardiomyopathy (DCM)s caused by humoral autoimmune response to 1AR. The BHV-1600 API will be formulated into the drug product for testing or for use in toxicology studies to evaluate safety and efficacy in disease treatment in living organisms. The BHV-1600 will be imported in two different forms as follows: 1. API formulated in a solution. 2.
Sterile drug product solution in glass vials.
You inquired about whether the imported BHV-1600 qualifies for duty free treatment as a prototype under subheading 9817.85.01, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” You indicated that Biohaven will import the BHV-1600 for further drug development in limited non-commercial quantities in accordance with industry practice solely to conduct FDA clinical trials and toxicology studies.
You further indicate that Biohaven will not incorporate BHV-1600 into other products that will be sold and any remaining BHV-1600 will be disposed of in accordance with applicable regulations. Finally, you state that BHV-1600 is not subject to any of the restrictions detailed in paragraph (c) of U.S. Note 7 to Chapter 98, HTSUS.
Based on the information presented, we find that BHV-1600, imported in two different forms, qualifies for duty free treatment as a prototype under subheading 9817.85.01, HTSUS, provided that all of the conditions delineated in U.S. Note 7, Chapter 98, Subchapter XVII, Harmonized Tariff Schedule of the United States, (HTSUS) are satisfied.
The applicable subheading for the subject merchandise will be 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” The rate of duty will be free. Please note a statistical classification in chapters 1-97 for subheading 9817.85.01, HTSUS, is also required.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N355252).